Valeant Pharmaceuticals

Valeant Pharmaceuticals shares slip after US FDA rejects Duobrii lotion for plaque psoriasis

Valeant has requested a meeting with the FDA and is working to overturn its decision

Scientist with a microscope
Valeant shares are down sharply on news of the FDA's denial

The US Food and Drug Administration has failed to approve Valeant Pharmaceuticals International Inc’s (NYSE:VRX) new lotion for the treatment of plaque psoriasis.

In its complete response letter to Valeant laying out its decision, US health regulators posed questions regarding pharmacokinetic data, but did not specify any problems relating to the effectiveness or safety of Duobrii, the lotion.

The Canadian company has requested a meeting with the FDA and is working to resolve the matter as it looks to find a way to bring Duobrii to market.

In cases of plaque psoriasis, the most common type of its kind, the skin is red and inflamed and covered with silvery scales.

Valeant shares fell 12% to close at US$23.54, but the stock is still up roughly 76% over the last year.

Quick facts: Valeant Pharmaceuticals

Price: £0.00

Market: TSX
Market Cap: £0.00

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Buds & Duds: Cannabis stocks flat as a pancake but CROP shares jump on first...

Cannabis stocks cruised into Friday flat as a pancake across North American markets. Buds today were CROP Infrastructure Corp (CSE:CROP) (OTCMKTS:CRXPF), True Leaf Brands Inc (CSE:MJ) (OTCMKTS:TRLFF), while the duds were TerrAscend Corp (CSE:TER) (OTCMKTS:TRSSF),...

20 hours, 23 minutes ago

2 min read